NASDAQ:SMMT Summit Therapeutics (SMMT) Stock Forecast, Price & News $1.65 +0.10 (+6.45%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$1.58▼$1.6750-Day Range$1.32▼$2.1752-Week Range$0.66▼$5.78Volume803,264 shsAverage Volume1.82 million shsMarket Capitalization$1.15 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Summit Therapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.75% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 5 Articles This WeekInsider TradingAcquiring Shares$412.29 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.40 out of 5 starsMedical Sector937th out of 1,018 stocksPharmaceutical Preparations Industry471st out of 498 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Summit Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.75% of the outstanding shares of Summit Therapeutics have been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Summit Therapeutics has recently increased by 2.76%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SMMT. Previous Next 2.1 News and Social Media Coverage News SentimentSummit Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Summit Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 30 people have searched for SMMT on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $412,292,984.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders83.70% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.59% of the stock of Summit Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 8.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Summit Therapeutics (NASDAQ:SMMT) StockSummit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.Read More Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SMMT Stock News HeadlinesMay 26, 2023 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Trading Down 5.9%May 26, 2023 | americanbankingnews.comTraders Buy High Volume of Summit Therapeutics Call Options (NASDAQ:SMMT)May 27, 2023 | Legacy Research (Affiliate) (Ad)Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New ForecastHe predicted the 2020 crash a month before it happened… He predicted this year’s collapse back in January…May 22, 2023 | finance.yahoo.com11 Stocks with Heavy Insider Buying in 2023May 18, 2023 | finance.yahoo.comAfter buying recently, Summit Therapeutics Inc. (NASDAQ:SMMT) insiders must be dismayed to see the company's market cap drop to US$1.2bMay 18, 2023 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $1.83May 16, 2023 | finance.yahoo.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q1 2023 Earnings Call TranscriptMay 16, 2023 | finance.yahoo.comWhy Shares of Summit Therapeutics Slumped on TuesdayMay 27, 2023 | Stansberry Research (Ad)Why 2023 Could Kick Off a "Cash Frenzy" in StocksBut the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.May 13, 2023 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Downgraded by StockNews.com to "Sell"May 12, 2023 | finance.yahoo.comQ1 2023 Summit Therapeutics Inc Earnings CallMay 11, 2023 | seekingalpha.comSummit Therapeutics, Inc. (SMMT) Q1 2023 Earnings Call TranscriptMay 11, 2023 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023May 11, 2023 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $1.94April 13, 2023 | seekingalpha.comSummit Therapeutics: Another Billionaire Project That Isn't Going AnywhereApril 12, 2023 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Shares Up 6%April 8, 2023 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $1.57March 23, 2023 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.6%March 21, 2023 | businesswire.comINVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the FirmMarch 21, 2023 | reuters.comSMMT.OMarch 13, 2023 | insidermonkey.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q4 2022 Earnings Call TranscriptMarch 9, 2023 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022March 3, 2023 | finance.yahoo.comSummit Therapeutics Closes Fully-Subscribed $500 Million Rights OfferingFebruary 1, 2023 | finance.yahoo.comBullish insiders bet US$97m on Summit Therapeutics Inc. (NASDAQ:SMMT)January 30, 2023 | finance.yahoo.comSummit Therapeutics Announces Timing for Rights Offering for Up to $500 MillionJanuary 20, 2023 | msn.comSummit closes license deal for antibody therapy for cancer; $500M rights offering on trackJanuary 5, 2023 | finance.yahoo.comWe Think Summit Therapeutics (NASDAQ:SMMT) Can Afford To Drive Business GrowthSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SMMT Company Calendar Last Earnings3/09/2023Today5/27/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SMMT CUSIPN/A CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees105Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,780,000.00 Net Margins-1,012.41% Pretax Margin-17,289.16% Return on Equity-70.92% Return on Assets-26.95% Debt Debt-to-Equity Ratio0.75 Current Ratio14.22 Quick Ratio14.22 Sales & Book Value Annual Sales$700,000.00 Price / Sales1,644.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book8.68Miscellaneous Outstanding Shares697,680,000Free Float113,723,000Market Cap$1.15 billion OptionableOptionable Beta-1.02 Key ExecutivesMr. Robert W. Duggan (Age 79)CEO & Exec. Chairman Dr. Mahkam Zanganeh D.D.S. (Age 53)M.B.A., MBA, Co-CEO, Pres & Director Comp: $651.45kDr. Urte Gayko Ph.D. (Age 52)Head of Regulatory Affairs, Quality Assurance & Safety and Director Comp: $7.76kProf. Dame Kay Davies DBE (Age 72)FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Mr. Ankur Dhingra (Age 47)Chief Financial Officer Ms. Michelle AveryDirector of Investor RelationsDr. Elaine Carla Stracker J.D. (Age 62)Ph.D., Head of Compliance? & Gen. Counsel Mr. Campbell HairHead of HR?Dr. Anne HeatheringtonHead of Clinical Devel. and Quantitative SciencesMs. Divya Chari (Age 55)Head of Global Clinical Operations More ExecutivesKey CompetitorsCTI BioPharmaNASDAQ:CTICTaro Pharmaceutical IndustriesNYSE:TAROOPKO HealthNASDAQ:OPKCrinetics PharmaceuticalsNASDAQ:CRNX89bioNASDAQ:ETNBView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 31,719 shares on 5/26/2023Ownership: 0.007%JPMorgan Chase & Co.Bought 9,522 shares on 5/18/2023Ownership: 0.003%State Street CorpBought 34,400 shares on 5/16/2023Ownership: 0.018%Jane Street Group LLCSold 12,300 shares on 5/16/2023Ownership: 0.000%Sea Otter Advisors LLCBought 17,266 shares on 5/16/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions SMMT Stock - Frequently Asked Questions How have SMMT shares performed in 2023? Summit Therapeutics' stock was trading at $4.25 on January 1st, 2023. Since then, SMMT shares have decreased by 61.2% and is now trading at $1.65. View the best growth stocks for 2023 here. When is Summit Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our SMMT earnings forecast. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics Inc. (NASDAQ:SMMT) issued its earnings results on Thursday, March, 9th. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $1.13 million for the quarter. Summit Therapeutics had a negative trailing twelve-month return on equity of 70.92% and a negative net margin of 1,012.41%. What ETFs hold Summit Therapeutics' stock? ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP). When did Summit Therapeutics IPO? (SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager. What is Summit Therapeutics' stock symbol? Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT." Who are Summit Therapeutics' major shareholders? Summit Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (0.90%), BlackRock Inc. (0.26%), Geode Capital Management LLC (0.16%), Steward Partners Investment Advisory LLC (0.09%), Two Sigma Investments LP (0.07%) and HRT Financial LP (0.06%). Insiders that own company stock include Ankur Dhingra, David Jonathan Powell, Mahkam Zanganeh, Maky Zanganeh and Robert W Duggan. View institutional ownership trends. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Summit Therapeutics' stock price today? One share of SMMT stock can currently be purchased for approximately $1.65. How much money does Summit Therapeutics make? Summit Therapeutics (NASDAQ:SMMT) has a market capitalization of $1.15 billion and generates $700,000.00 in revenue each year. The company earns $-78,780,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis. How many employees does Summit Therapeutics have? The company employs 105 workers across the globe. How can I contact Summit Therapeutics? Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The official website for the company is www.summitplc.com. The company can be reached via phone at 650-460-8308, via email at investors@summitplc.com, or via fax at 44-12-3544-3999. This page (NASDAQ:SMMT) was last updated on 5/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.